- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02698059
A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea
A Multi-center, Two-stage, Single-arm, Prospective, First-night Order Cross-over, Evaluator-blind Study to Evaluate the Efficacy, Safety and Tolerance of the iNAP® Sleep Therapy System in Adults With Obstructive Sleep Apnea (OSA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: C.C. Chen, Ph.D.
- Email: chungchu1@somnics.com
Study Contact Backup
- Name: C.N. Huang, Ph.D.
- Email: huangcn@somnics.com
Study Locations
-
-
-
Cologne, Germany
- Recruiting
- INTERSOM
-
Contact:
- Lennart Knaack
-
Dortmund, Germany
- Recruiting
- Somnolab
-
Contact:
- Hans-Christian Blum
-
Essen, Germany
- Recruiting
- Alfred Krupp Krankenhaus
-
Contact:
- Ricardo Stoohs
-
Frankfurt, Germany
- Recruiting
- American Sleep Clinic
-
Contact:
- Hartmut Schneider
-
Hagen, Germany
- Recruiting
- Helios Klinik Ambrock
-
Contact:
- Georg Nilius
-
Solingen, Germany
- Recruiting
- Krankenhaus Bethanien
-
Contact:
- Randerath
-
-
-
-
-
Taipei, Taiwan, 104
- Recruiting
- Mackay Memorial Hospital
-
Contact:
- Ying-Piao Wang
-
Taipei, Taiwan, 111
- Recruiting
- Shin Kong Wu Ho-Su Memorial Hospital
-
Contact:
- Chia-Mo Lin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1) Female or male adults with age between 18~65 years old. (S1)
- 2) Non-obese patients with body mass index (BMI) <29 kg/m2. (S1)
- 3) Patients able to read and sign on the informed consent form and able to comply with study requirements. (S1)
- 4) Patients able to be properly fitted* with the oral interface as observed by the device feasibility test. (S1)
- 5) Patients with oxygen desaturation index (ODI) between 10~40 (S2).
6) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and total sleep time (TST) ≥4 hours/night (S3).
- iNAP® pressure more negative than -30 mmHg will be considered evidence of effective oral appliance application.
- 7) Patients with apnea-hypopnea index (AHI) between 10~40 and TST ≥4 hours/night (Baseline PSG Night).
8) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and TST ≥4 hours/night (1st Tx PSG Night).
- iNAP® pressure more negative than -30 mmHg will be considered evidence of effective oral appliance application.
Exclusion Criteria:
- 1) Patients who are allergic to silicone.
- 2) Patients with obstructed nasal passages as evidenced by the inability to breathe through the nose with the mouth closed.
- 3) Patients who recently experienced a near-miss or prior automobile accident due to sleepiness.
- 4) Patients who have or have had hypoxemia (SpO2 <80%) in the past six months caused by diseases other than OSA such as cardiac disease or severe pulmonary/respiratory disorders such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, pneumothorax, pneumonia, etc.
- 5) Female patients who are lactating, pregnant or intend to become pregnant during the study period.
- 6) Patients with primary insomnia or any concomitant diagnosed or suspected sleep disorder.
7) Patients with muscle disease, central nervous disease or chronic neurological disorders, including central sleep apnea*.
- Central sleep apnea is defined as a central apnea index (CAI) ≥ 5/hr or if central sleep apnea accounts for ≥ 50% of the total AHI.
- 8) Patients in whom it is not suitable to use iNAP® in the opinion of the Investigator including, but not limited to, alcohol or substance abuse, loose teeth, missing teeth, or grinding teeth, completed deviated septum (Type IV or VII) or completed closed nostrils or advanced periodontal disease or tonsillar volumes greater than grade 3.
- 9) Patients with an inability to sleep through the night including, but not limited to, menopausal hot flashes, working at nights or rotating night shifts, planned travel across four or more time zones during the study period or within one week prior to study participation, or a sleep schedule not compatible with study site practices.
- 10) Patients with potential complications of sleep apnea that, in the opinion of the Investigator, may affect the study interpretation or the health or safety of the patients including, but not limited to, narcolepsy, restless leg syndrome, nasopharyngeal carcinoma (NPC), end stage renal failure, a history of severe cardiovascular disease (including New York Heart Association (NYHA) class III or IV cardiac failure, coronary artery disease with angina or myocardial infarction/stroke in the past six months, uncontrolled hypertension or hypotension or cardiac arrhythmias), unstable heart or renal transplantation or use of medicine or other treatment(s) that may confound the result of the study or pose additional risks to the patient, such as oral anticoagulants or other agents making patients prone to tongue hemorrhage.
Stage II Inclusion Criteria:
Patients who fulfill all the enrollment criteria of Stage I and whose treated AHI on the 1st Tx PSG Night is below 40.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treated
iNAP® Sleep Therapy System Treatment
|
The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
|
No Intervention: Baseline/Control
Self-controlled, pre-treatment baseline
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success rate* of apnea-hypopnea index (AHI)** on the 1st Tx PSG Night when compared to the Baseline PSG Night.
Time Frame: first treatment night
|
*Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of >50% and treated AHI <20 to the number of patients who complete the 1st Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 1st Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met. **AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep. |
first treatment night
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AE/SAE rate and type
Time Frame: The whole study period through study completion; up to 8 weeks
|
Vital signs, Physical examination (PE) findings and change of body figure indexes, Electrocardiogram (ECG) findings as reflected in polysomnography (PSG), Adverse events (AEs), Serious adverse events (SAEs), Changes in the oral and dental condition
|
The whole study period through study completion; up to 8 weeks
|
Clinical success rate* of apnea-hypopnea index (AHI)** on the 2nd Tx PSG Night when compared to the 1st Tx PSG Night.
Time Frame: second treatment night
|
*Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of >50% and treated AHI <20 to the number of patients who complete the 2nd Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 2nd Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met. **AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep. |
second treatment night
|
Change of Oxygen Desaturation Index (ODI)* from the Baseline PSG Night compared to the 1st Tx PSG Night and the 2nd Tx PSG Night; and the change from the 1st Tx PSG Night compared to the 2nd Tx PSG Night.
Time Frame: At the Baseline PSG Night, the 1st Tx PSG Night and/or the 2nd Tx PSG Night
|
*ODI is the event number of oxygen level drops by 3 percent or more from baseline divided by total sleep time (TST), i.e., the number of hours of sleep.
|
At the Baseline PSG Night, the 1st Tx PSG Night and/or the 2nd Tx PSG Night
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hartmut Schneider, M.D., American Sleep Clinic Frankfurt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- iNAP®-CE-1501
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Sleep Apnea (OSA)
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
Hospital for Special Surgery, New YorkCompletedObstructive Sleep Apnea (OSA)
-
Mayo ClinicCompletedObstructive Sleep Apnea (OSA)United States
-
ResMedCompletedObstructive Sleep Apnea (OSA)United States, Australia
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
ApnimedCompletedOSA - Obstructive Sleep ApneaUnited States
-
Tufts Medical CenterRespiratory Motion, Inc.Active, not recruitingObstructive Sleep Apnea (OSA)United States
-
Weill Medical College of Cornell UniversityTerminatedObstructive Sleep Apnea (OSA)United States
-
Weill Medical College of Cornell UniversityCornell UniversityWithdrawn
Clinical Trials on iNAP® Sleep Therapy System (iNAP)
-
Somnics, Inc.Completed
-
Somnics, Inc.UnknownObstructive Sleep Apnea of AdultTaiwan
-
Somnics, Inc.TerminatedObstructive Sleep ApneaTaiwan
-
Shin Kong Wu Ho-Su Memorial HospitalNational Yang Ming Chiao Tung UniversityRecruiting
-
Karolinska InstitutetRecruitingDyssomnias | Sleep Disorder | Insomnia | Alcohol Use DisorderSweden
-
The University of Hong KongAspire Bariatrics, Inc.Unknown
-
University of StrathclydeUniversity of Oxford; NHS Greater Glasgow and Clyde; NHS Grampian; University of...Not yet recruitingAcute Insomnia (Disorder)
-
University of Alabama, TuscaloosaTerminatedSleep Initiation and Maintenance DisordersUnited States
-
Inspire Medical Systems, Inc.Active, not recruiting
-
Monteris MedicalCompletedPrimary Brain TumorUnited States